News Column

MMRGlobal Subsidiary Gets Clinical Trials Patent

July 18, 2014

MMRGlobal, through its wholly owned subsidiary, MyMedicalRecords (collectively, "MMR"), said that it has received a new patent from the United States Patent and Trademark Office entitled "Electronic Health Records in Clinical Trials."

In its release, the Company said that the newly issued patent, U.S. Patent No. 8,775,212, opens the door to completely new revenue generating opportunities for the Company through sales and licensing of MMR's Personal Health Record ("PHR") products and services and other patented intellectual property ("Patented IP") to Contract Research Organizations ("CROs") and pharmaceutical companies conducting clinical trials. According to, there are currently 170,766 studies occurring in all 50 states and in 187 countries being conducted by numerous CROs, universities and pharmaceutical companies. CROs, Big Pharma and pharmaceutical start- ups are consistently looking for ways to reduce costs and speed up the clinical trial process. MMR's products, services and patented IP are designed to help reduce trial costs and shorten trial times. Accordingly, MMR plans on providing access to its Patented IP and products and services in consideration of traditional sales and licensing agreements or by participation in long-term success based outcomes from clinical trials.

MMR said that its '212 patent is the first in a new family of patents using electronic forms of self-reporting to provide data in clinical trials. On July 9th, the day after MMR received its new clinical trials patent, a study from the University of Texas Southwestern Medical Center, published in the Journal of Oncology Practice, reported that over a six-year period, the number of patients actively using a PHR each year increased five-fold, while the number of total logins each year increased more than 10-fold. Two days later, The University of Manchester's Health eResearch Centre in the UK issued an article, Better Use of Electronic Health Records Makes Clinical Trials Less Expensive, predicting better outcomes for patients by helping them understand the treatments in both cardiovascular disease and chronic obstructive pulmonary disease.

According to MMRGlobal CEO Robert H. Lorsch, "The '212 patent is a whole new patent, not a continuation patent. This patent will allow MMR to potentially generate revenue from licensing to organizations that routinely conduct clinical trials for Big Pharma. Because clinical trials are extremely time consuming and expensive, we believe the '212 patent and additional continuation patents coming from this patent will be of significant value to the company and that this value is not reflected in previous valuations of the Company's patents, which have ranged from $600,000,000 to 1.3 billion dollars."

More Information and Complete Details:

((Comments on this story may be sent to

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Health & Beauty Close - Up

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters